Alleviate Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 28-06-2024
- Paid Up Capital ₹ 1.00 M
as on 28-06-2024
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.50 M
as on 28-06-2024
- Revenue 16.09%
(FY 2020)
- Profit 21.50%
(FY 2020)
- Ebitda 73.67%
(FY 2020)
- Net Worth 1979.57%
(FY 2020)
- Total Assets 5.06%
(FY 2020)
About Alleviate Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹3.50 M.
Maheepal and Sanjiv Kumar serve as directors at the Company.
- CIN/LLPIN
U24232HR2015PTC077954
- Company No.
077954
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jan 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Panchkula, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Alleviate Pharmaceuticals Private Limited offer?
Alleviate Pharmaceuticals Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Muscle Relaxant, Anti Infective Drugs & Medicines, Anti Allergic Drug, Drotaverine Hydrochloride Mefenamic Acid Tablet, Antacid Drugs, Rabeprazole Domperidone Capsule, Antibiotic Tablets & Capsules, Cefixime Tablet, Antihistamines.
Who are the key members and board of directors at Alleviate Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Maheepal  | Director | 08-Oct-2015 | Current |
| Sanjiv Kumar | Director | 05-Jan-2015 | Current |
Financial Performance and Corporate Structure Insights of Alleviate Pharmaceuticals.
Alleviate Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 16.09% increase. The company also saw a substantial improvement in profitability, with a 21.5% increase in profit. The company's net worth Soared by an impressive increase of 1979.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alleviate Pharmaceuticals?
In 2020, Alleviate Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 01 Jul 2016 | ₹3.50 M | Open |
How Many Employees Work at Alleviate Pharmaceuticals?
Unlock and access historical data on people associated with Alleviate Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Sep 11, 2018, Alleviate Pharmaceuticals has raised a total of ₹ 0.9 M, with the most recent deal valued at ₹ 0.9 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
